Texas Medical Cannabis Program: Compassionate Use & Low-THC Regulations

Executive Summary

Texas operates one of the most restrictive medical cannabis programs in the United States, limiting access to low-THC cannabis products for a narrow list of qualifying conditions through a tightly controlled dispensary licensing system. The Texas Compassionate Use Program (TCUP), established in 2015 and incrementally expanded through subsequent legislative sessions, permits only state-licensed dispensing organizations to cultivate, process, and distribute medical cannabis products containing no more than 1% THC by weight. As of 2026, the program serves approximately 75,000 registered patients across conditions including epilepsy, terminal cancer, PTSD, and autism. The state's Department of Public Safety maintains strict oversight through the Compassionate Use Registry of Texas (CURT), requiring physician registration, patient certification, and comprehensive seed-to-sale tracking. Recent regulatory developments, including the controversial revocation of conditional licenses issued to multi-state operators like Cresco Labs in May 2026, have highlighted ongoing tensions between Texas's conservative approach to cannabis policy and pressure from patients, advocates, and industry stakeholders seeking meaningful program expansion. The program's limited scope—excluding smokable flower, restricting THC potency, and maintaining a closed vertical integration model—places Texas among the most conservative medical cannabis states despite serving the nation's second-largest population.

Why This Matters

Texas's medical cannabis program affects 30 million residents in the nation's second-most-populous state, representing a market that could exceed $1 billion annually under moderate expansion scenarios. The program's restrictive parameters have created a unique policy laboratory where conservative governance intersects with growing patient demand and evolving medical evidence. Approximately 75,000 Texans currently access medical cannabis through TCUP, but advocacy organizations estimate that 1.5 to 2 million residents could qualify under conditions recognized in other medical states. The economic implications extend beyond patient access: Texas's limited licensing structure has created artificial scarcity, with the state's licensed dispensing organizations generating an estimated $150-200 million in annual revenue despite serving a fraction of potential patients. Healthcare providers face complex decisions balancing federal restrictions, state regulations, and patient needs. Over 2,800 physicians have registered with CURT to recommend cannabis, navigating liability concerns and evolving clinical guidelines. Veterans organizations have been particularly vocal advocates, noting that approximately 1.5 million Texas veterans could benefit from cannabis access for PTSD and chronic pain management. The program's structure also impacts national cannabis policy debates. As the largest conservative-leaning state with medical cannabis, Texas serves as a bellwether for Republican-controlled legislatures considering similar programs. Industry stakeholders monitor Texas closely: successful entry into the market represents access to massive population centers including Houston, Dallas-Fort Worth, San Antonio, and Austin metropolitan areas. The May 2026 license revocations sent shockwaves through cannabis capital markets, demonstrating how regulatory uncertainty in major states affects national investment flows and MSO valuations. Agricultural interests also have stakes in program evolution. Texas's 248,000 farms could diversify into hemp and cannabis cultivation under expanded programs, potentially generating hundreds of millions in new agricultural revenue for rural communities facing economic pressures.

Background and History

Texas's medical cannabis program evolved through a decade of incremental legislative expansions, beginning with the 2015 Compassionate Use Act and continuing through successive sessions that gradually broadened qualifying conditions while maintaining strict THC limits and vertical integration requirements.

The Compassionate Use Act (2015)

The Texas Legislature passed the Compassionate Use Act during the 84th Legislative Session in 2015, signed into law by Governor Greg Abbott as Senate Bill 339. The original legislation, sponsored by Senator Kevin Eltife, created the nation's most restrictive medical cannabis program, permitting only low-THC cannabis oil (defined as containing no more than 0.5% THC by weight and at least 10% CBD) for patients with intractable epilepsy. The bill's passage represented a significant shift in Texas cannabis policy, driven primarily by testimony from families of children suffering from severe seizure disorders who had relocated to Colorado and other states to access cannabis treatment. The Department of Public Safety received regulatory authority to establish the Compassionate Use Registry of Texas and license up to three dispensing organizations statewide. The vertical integration requirement mandated that each licensee control cultivation, processing, and distribution, creating a closed-loop system designed to maximize regulatory oversight. The program's initial implementation faced delays, with the first dispensaries not operational until 2017, two years after legislative authorization.

House Bill 3703 and Initial Expansion (2019)

The 86th Legislative Session in 2019 brought the first significant program expansion through House Bill 3703, authored by Representative Stephanie Klick. This legislation expanded qualifying conditions beyond intractable epilepsy to include terminal cancer, multiple sclerosis, spasticity, amyotrophic lateral sclerosis (ALS), autism, and seizure disorders more broadly. The bill also increased the THC cap from 0.5% to 1% by weight, though this remained far below the 5-30% THC content typical in other medical states. HB 3703 eliminated the previous requirement that two physicians confirm an epilepsy diagnosis, streamlining the recommendation process. The legislation also protected physicians from professional sanctions for recommending cannabis within program parameters, addressing a significant barrier to provider participation. By the end of 2019, approximately 1,200 patients had registered with CURT, a modest number reflecting both the program's limited scope and ongoing implementation challenges.

House Bill 1535 and PTSD Inclusion (2021)

The 87th Legislative Session in 2021 marked another expansion milestone with House Bill 1535, again sponsored by Representative Klick. This legislation added post-traumatic stress disorder (PTSD) and all forms of cancer to the qualifying conditions list, responding to intense advocacy from veterans organizations and oncology specialists. The inclusion of PTSD was particularly significant given Texas's large veteran population and growing medical evidence supporting cannabis for trauma-related conditions. HB 1535 also expanded the THC cap to include measurement by volume in addition to weight, providing regulatory flexibility for different product formulations. The legislation directed DPS to increase the number of licensed dispensing organizations, though it did not specify exact numbers, leaving expansion timelines to regulatory discretion. Patient enrollment accelerated following the 2021 changes, reaching approximately 25,000 registered patients by year-end.

House Bill 1805 and Chronic Pain Addition (2023)

The 88th Legislative Session in 2023 brought the most substantial expansion to date through House Bill 1805. This legislation added chronic pain to the qualifying conditions list, potentially expanding the eligible patient population by hundreds of thousands. The bill defined qualifying chronic pain as pain lasting longer than three months that is either related to a qualifying condition or for which conventional therapeutic interventions have proven ineffective. HB 1805 also directed DPS to issue additional dispensing organization licenses, moving from the original three-license cap toward a more competitive market structure. The legislation maintained the 1% THC limit but removed the previous CBD concentration requirement, allowing dispensaries to formulate products based on patient and physician preferences. By late 2023, patient enrollment had grown to approximately 50,000, with projections suggesting 75,000-100,000 patients by 2025.

The 2024-2025 Licensing Expansion

In response to HB 1805's directive, the Texas Department of Public Safety announced in January 2024 that it would accept applications for twelve additional dispensing organization licenses, bringing the total to fifteen statewide. The application window opened in March 2024 and closed in June 2024, attracting over 100 applicants including established Texas cannabis operators, multi-state operators, and new entrants backed by private equity. DPS announced conditional license awards in December 2024, including three licenses to multi-state operators: Cresco Labs (Chicago), Trulieve (Florida), and Curaleaf (Massachusetts). The awards marked the first time out-of-state operators received Texas medical cannabis licenses, signaling potential market maturation. However, the conditional licenses required extensive background checks, financial disclosures, and facility inspections before final approval.

The May 2026 License Revocations

On May 11, 2026, DPS abruptly rescinded three conditional licenses, including Cresco Labs' permit, citing unspecified "deficiencies in application materials and compliance documentation." The agency provided minimal public explanation, stating only that the revoked licensees failed to meet statutory and regulatory requirements during the conditional approval period. The revocations occurred without prior warning or opportunity for remediation, sparking immediate legal challenges and industry outcry. The revocations reduced the planned license expansion from twelve to nine new operators, maintaining market concentration among existing Texas-based dispensaries. Industry analysts speculated that political pressure from incumbent licensees, concerns about out-of-state capital, or undisclosed compliance issues drove the decision. Cresco Labs issued a statement expressing disappointment and indicating potential legal action, while patient advocates criticized the move as prioritizing incumbent business interests over patient access.

Key Players

The Texas medical cannabis landscape involves state agencies, licensed dispensing organizations, advocacy groups, legislative champions, and opposition forces, each shaping program development through distinct roles and interests.

Texas Department of Public Safety

The Department of Public Safety serves as the primary regulatory authority for TCUP, operating the Compassionate Use Registry of Texas and overseeing all licensing, compliance, and enforcement activities. DPS Director Steven McCraw has maintained a conservative regulatory approach, emphasizing public safety and diversion prevention over market expansion. The agency's Regulatory Services Division processes physician registrations, patient certifications, and dispensary compliance reports, maintaining one of the most comprehensive cannabis tracking systems in the nation. DPS's May 2026 license revocations demonstrated the agency's broad discretionary authority over market entry, raising questions about transparency and due process in licensing decisions. The agency operates with limited legislative oversight between sessions, creating regulatory uncertainty that affects investment decisions and market planning.

Texas Original Compassionate Cultivation

Texas Original Compassionate Cultivation, based in Austin, was among the first three dispensing organizations licensed in 2017. The company operates cultivation and processing facilities in southeast Austin and maintains dispensaries in Austin, Houston, and Dallas. As a founding operator, Texas Original has advocated for measured program expansion while defending the vertical integration model and limited licensing structure that protects incumbent market positions. The company has invested heavily in compliance infrastructure, genetic research, and product development within the 1% THC constraint, developing proprietary formulations for different qualifying conditions. Texas Original reported approximately $45-50 million in annual revenue as of 2025, serving an estimated 20,000-25,000 patients across its three locations.

Compassionate Cultivation

Compassionate Cultivation, headquartered in Manchaca near Austin, operates as another original licensee with facilities in central Texas and dispensaries in San Antonio, Austin, and the Rio Grande Valley. The company has emphasized patient education and physician outreach, building relationships with healthcare providers skeptical of cannabis medicine. Compassionate Cultivation has been active in legislative advocacy, supporting incremental expansions while opposing dramatic regulatory changes that could destabilize the existing market structure. The company pioneered several product innovations within program constraints, including condition-specific formulations and precise dosing mechanisms designed for elderly patients and children. Annual revenue estimates range from $40-45 million, with patient counts similar to Texas Original.

Surterra Wellness Texas

Surterra Wellness Texas, the third original licensee, operates cultivation facilities in north Texas and maintains dispensaries in Dallas, Fort Worth, and Houston. The company is affiliated with Parallel, a multi-state operator with operations in Florida, Massachusetts, and other states, providing capital and operational expertise that smaller Texas operators lack. Surterra has invested in advanced cultivation technologies, producing consistent, pharmaceutical-grade products that meet strict state testing requirements. The company has been less publicly vocal in policy debates than other incumbents but maintains significant lobbying presence in Austin. Surterra's estimated annual Texas revenue approaches $50-55 million, making it the largest of the original three licensees by market share.

Cresco Labs

Chicago-based Cresco Labs, one of the nation's largest cannabis MSOs with operations in ten states, received a conditional Texas license in December 2024 as part of the expansion round. The company planned to invest $25-30 million in Texas cultivation and processing facilities, bringing sophisticated operations and national brand recognition to the state market. Cresco's May 2026 license revocation represented a significant setback, eliminating projected Texas revenue of $75-100 million annually within three years. The company has indicated potential legal challenges to the revocation, arguing that DPS failed to provide adequate notice or opportunity to address alleged deficiencies. Cresco's experience highlights risks that multi-state operators face when entering tightly controlled state markets with limited regulatory transparency.

Texas NORML

The Texas chapter of the National Organization for the Reform of Marijuana Laws serves as the state's primary cannabis policy reform advocacy organization. Texas NORML has pushed for comprehensive medical cannabis expansion, including higher THC limits, smokable flower access, additional qualifying conditions, and eventual adult-use legalization. The organization coordinates patient testimony for legislative hearings, conducts public education campaigns, and tracks voting records on cannabis legislation. Executive Director Jax Finkel has been a prominent voice criticizing the program's restrictive nature, arguing that Texas's 1% THC limit and limited conditions list fail to serve patients with serious medical needs. The organization supported the 2024 license expansion but condemned the 2026 revocations as politically motivated interference with patient access.

Texans for Responsible Marijuana Policy

Texans for Responsible Marijuana Policy represents a coalition of patient advocates, healthcare providers, and reform organizations pushing for evidence-based cannabis policy. The group has focused on educating legislators about medical cannabis research, organizing patient lobby days, and countering prohibitionist messaging. The coalition played a significant role in the PTSD and chronic pain expansions, providing compelling patient testimony that swayed conservative legislators. The organization maintains that Texas could serve 1-2 million patients under a properly designed medical program, generating hundreds of millions in economic activity while improving health outcomes for veterans, cancer patients, and chronic pain sufferers.

Law Enforcement Opposition

Several Texas law enforcement organizations, including county sheriffs' associations and police chiefs' groups, have historically opposed cannabis policy reforms. These groups argue that expanded access increases impaired driving risks, complicates workplace safety, and creates enforcement challenges distinguishing legal medical use from illegal possession. While opposition has softened somewhat as medical evidence has accumulated, law enforcement voices remain influential with conservative legislators skeptical of cannabis policy changes. Sheriff associations have particularly opposed higher THC limits and smokable flower, arguing these products more closely resemble recreational cannabis and increase diversion risks. This opposition has contributed to Texas maintaining the nation's lowest THC cap for medical products.

Texas Medical Association

The Texas Medical Association, representing over 55,000 physicians statewide, has maintained a cautious position on medical cannabis, neither strongly supporting nor opposing program expansions. The TMA has emphasized the need for additional clinical research, standardized dosing guidelines, and liability protections for recommending physicians. The organization supported PTSD and cancer additions to qualifying conditions based on emerging evidence but has not advocated for comprehensive program liberalization. Individual TMA members span the spectrum from cannabis medicine advocates to skeptics concerned about federal illegality and limited FDA approval. This diversity has kept the organization's official positions relatively neutral, focusing on patient safety and physician discretion rather than policy advocacy.

Legal and Regulatory Framework

Texas medical cannabis operates under a complex legal structure balancing state statutory authorization with federal prohibition, creating a regulatory environment defined by strict controls, limited judicial interpretation, and ongoing federalism tensions. The foundational legal authority for TCUP derives from Texas Health and Safety Code Chapter 169, enacted through the Compassionate Use Act and subsequent amendments. Section 169.001 establishes legislative findings that low-THC cannabis may benefit patients with certain debilitating conditions, while Section 169.002 provides definitions including the critical "low-THC cannabis" standard of not more than 1% THC by weight. These statutory provisions create a narrow legal pathway that distinguishes Texas medical cannabis from both recreational marijuana and the broader medical programs in other states. Texas Occupations Code Section 169.003 establishes the Compassionate Use Registry, requiring the Department of Public Safety to maintain a secure online database of qualified physicians and registered patients. The statute mandates that physicians complete a DPS-approved education course before registering, creating a knowledge baseline for recommending providers. Section 169.004 specifies qualifying conditions, currently including epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, terminal cancer, all cancer types, PTSD, and chronic pain meeting statutory criteria. The licensing framework appears in Section 169.005, authorizing DPS to issue dispensing organization licenses to entities meeting statutory requirements. The statute mandates vertical integration, requiring licensees to cultivate, process, and dispense all products, prohibiting the wholesale market structures common in other states. Section 169.006 establishes criminal and civil penalties for violations, including felony charges for unlicensed cultivation or distribution, creating strict liability for compliance failures. Texas Administrative Code Title 37, Part 1, Chapter 13 contains detailed regulatory provisions implementing the statutory framework. Rule 13.101 establishes physician registration requirements, including background checks, education completion, and ongoing reporting obligations. Rule 13.201 specifies patient registration procedures, requiring physician certification, identity verification, and annual renewal. Rule 13.301 through 13.350 govern dispensing organization operations, covering security requirements, testing protocols, inventory tracking, and product labeling. The regulatory framework requires all cannabis products to undergo testing by independent laboratories for potency, contaminants, pesticides, and microbials, with results reported to DPS before sale. Products must be packaged in child-resistant containers with comprehensive labeling including THC/CBD content, dosage instructions, and health warnings. Dispensaries must maintain video surveillance, alarm systems, and secure storage meeting DPS specifications. Federal law creates significant complications for Texas medical cannabis operations. The Controlled Substances Act classifies marijuana as a Schedule I substance, making cultivation, distribution, and possession federal crimes regardless of state authorization. This creates ongoing legal jeopardy for dispensing organizations, patients, and physicians, though federal enforcement priorities have generally avoided state-compliant medical programs. The Rohrabacher-Farr Amendment, periodically renewed in federal appropriations bills, prohibits the Department of Justice from using funds to interfere with state medical cannabis programs, providing limited protection. Federal illegality also creates banking challenges. The Bank Secrecy Act and anti-money laundering regulations make financial institutions reluctant to serve cannabis businesses, forcing many dispensaries to operate primarily in cash. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House multiple times but has not become law, leaving Texas operators in regulatory limbo. Texas courts have provided limited interpretation of TCUP provisions, as the program's recent vintage and narrow scope have generated few legal challenges. In State v. Rodriguez (2022), the Texas Court of Criminal Appeals held that possession of cannabis exceeding the 1% THC limit remains illegal even for registered patients, affirming that TCUP creates a narrow exception to general marijuana prohibition rather than broad medical use authorization. In Davis v. Texas Department of Public Safety (2023), a state district court upheld DPS's discretion in licensing decisions, finding that applicants have no property interest in licenses before final issuance. The May 2026 license revocations will likely generate significant litigation testing the boundaries of DPS authority, due process requirements, and the rights of conditional licensees. Legal observers expect challenges based on Administrative Procedure Act violations, arbitrary and capricious agency action, and potentially equal protection claims if revocations targeted out-of-state operators. Workplace and housing protections remain limited under Texas law. Employers may terminate employees for medical cannabis use, and landlords may prohibit possession in rental properties, as TCUP does not create employment or housing discrimination protections. This contrasts with states like Arizona and New Jersey that have enacted explicit protections for medical cannabis patients.

State-by-State Context: How Texas Compares

Texas's medical cannabis program ranks among the nation's most restrictive, with its 1% THC limit, narrow qualifying conditions, and limited licensing structure contrasting sharply with comprehensive programs in other large states.

State	THC Limit	Qualifying Conditions	Smokable Flower	License Structure	Registered Patients
Texas	1% by weight	11 specific conditions	No	15 vertical licenses	~75,000
Florida	No limit	Broad physician discretion	Yes	25+ vertical licenses	~850,000
California	No limit	Broad physician discretion	Yes	Unlimited licenses	~1.2 million
Oklahoma	No limit	Physician discretion	Yes	Unlimited licenses	~375,000
Pennsylvania	No limit	23 specific conditions	Yes (since 2022)	Limited licenses	~425,000
Louisiana	No limit	Broad physician discretion	Yes	10 pharmacy licenses	~45,000

Florida: Comprehensive Access Model

Florida's medical cannabis program, established through a 2016 constitutional amendment, permits physicians to recommend cannabis for any condition they believe would benefit from treatment. The state licenses over 25 vertically integrated medical marijuana treatment centers with no THC limits, allowing full-potency products including smokable flower (authorized in 2019). With approximately 850,000 registered patients, Florida demonstrates the market potential when access barriers are reduced. The state's program generates over $2 billion in annual sales, illustrating the economic scale Texas forgoes with restrictive policies.

Oklahoma: Open Market Approach

Oklahoma operates the nation's most permissive medical cannabis program, with physician discretion for qualifying conditions and unlimited licensing for growers, processors, and dispensaries. The state has issued over 8,000 business licenses, creating intense competition and low prices that benefit patients but challenge business viability. With approximately 375,000 registered patients in a state of 4 million residents—roughly 9% of the population—Oklahoma demonstrates high participation rates when access barriers are minimal. Texas, with similar conservative political culture, could theoretically support 2-3 million patients under comparable policies.

Pennsylvania: Balanced Regulatory Model

Pennsylvania's program, launched in 2018, initially prohibited smokable flower but added it in 2022 following patient advocacy. The state recognizes 23 specific qualifying conditions, more than Texas but less than physician-discretion states. Pennsylvania's limited licensing structure (initially 25 grower/processors and 50 dispensaries) created a middle path between Texas's extreme restriction and Oklahoma's open market. With approximately 425,000 patients in a state of 13 million, Pennsylvania achieves roughly 3% population participation, suggesting Texas could support 900,000 patients under similar policies.

Louisiana: Pharmacy Distribution Model

Louisiana uniquely distributes medical cannabis through licensed pharmacies rather than dedicated dispensaries, integrating cannabis into existing healthcare infrastructure. The state authorizes ten pharmacy licenses with no THC limits and broad physician discretion for qualifying conditions. Despite these relatively permissive policies, Louisiana has only 45,000 registered patients, illustrating that program structure alone doesn't guarantee participation—factors like physician education, patient awareness, and cultural acceptance also matter significantly. The comparison reveals Texas as an outlier among large states, maintaining restrictions more typical of early-stage programs despite a decade of operation and multiple legislative expansions. The 1% THC limit particularly distinguishes Texas, as no other state with an established medical program maintains such low potency caps. This restriction forces patients seeking higher-potency products to either forgo treatment, relocate to other states, or access illegal markets, undermining program goals.

Market and Business Implications

Texas's restrictive medical cannabis program has created a constrained market with artificial scarcity, limited competition, and significant unrealized economic potential, while the May 2026 license revocations have intensified concerns about regulatory predictability and market access. The existing Texas medical cannabis market generates an estimated $150-200 million in annual revenue across the state's licensed dispensing organizations, serving approximately 75,000 patients. This translates to average annual patient spending of $2,000-2,700, comparable to other medical states despite Texas's lower THC limits. Product pricing reflects the limited competition, with monthly patient costs typically ranging from $150-300 depending on condition severity and dosing requirements. The vertical integration mandate concentrates capital requirements and operational complexity, creating significant barriers to entry. Establishing a compliant dispensing organization requires $10-20 million in initial capital for cultivation facilities, processing equipment, security systems, testing capabilities, and retail locations. This capital intensity, combined with limited licensing, has kept the market concentrated among well-funded operators with deep Texas connections or MSO backing. Wholesale markets do not exist in Texas due to vertical integration requirements, eliminating the independent cultivator and processor segments common in other states. This structure prevents specialization and economies of scale that could reduce costs and improve product quality. Dispensing organizations must maintain expertise across cultivation, extraction, formulation, and retail operations, increasing operational complexity and capital requirements. The May 2026 license revocations significantly impacted market expectations and valuations. Cresco Labs' stock declined 8% in the week following the announcement, while other MSOs with Texas exposure or expansion plans experienced similar declines. The revocations signaled that Texas market entry carries higher regulatory risk than previously understood, potentially deterring future investment and expansion efforts. Industry analysts estimate that Texas could support a $1-1.5 billion annual medical cannabis market under moderate expansion scenarios including higher THC limits, additional qualifying conditions, and increased licensing. More comprehensive reforms approaching Oklahoma or Florida models could generate $2-3 billion annually, creating thousands of jobs and hundreds of millions in state tax revenue. The current program captures perhaps 10-15% of this potential market, leaving substantial economic value unrealized. Employment in Texas medical cannabis remains limited, with the existing dispensing organizations employing an estimated 800-1,200 workers statewide across cultivation, processing, retail, and administrative functions. Expanded licensing and market growth could support 10,000-15,000 jobs under moderate scenarios, with comprehensive reform potentially creating 25,000-30,000 positions. Ancillary businesses including testing laboratories, security providers, legal services, and compliance software vendors have emerged to serve the Texas market, though at smaller scale than in states with larger programs. The state currently has approximately 15 licensed cannabis testing laboratories, compared to 50+ in Florida and 100+ in California, reflecting market size differences. Real estate implications remain modest given the limited number of licensed facilities. Dispensing organizations typically operate 10,000-50,000 square foot cultivation facilities and 1,500-3,000 square foot retail locations, with total statewide cannabis-dedicated real estate estimated at 300,000-500,000 square feet. Expanded licensing could increase this to 2-3 million square feet, creating opportunities for industrial landlords and developers. Banking challenges persist despite the program's state legality. Most Texas dispensing organizations maintain relationships with smaller credit unions or out-of-state banks willing to accept cannabis clients, paying premium fees for basic services. The lack of normal banking access increases operational costs, security risks, and administrative burdens, with estimates suggesting 10-15% cost premiums compared to businesses with standard banking relationships. Investment capital flows into Texas medical cannabis have been limited by both program restrictions and regulatory uncertainty. The 2026 license revocations will likely further constrain capital availability, as investors demand higher returns to compensate for regulatory risk. Private equity firms and institutional investors that might otherwise fund Texas expansion are deterred by the combination of federal illegality, state program limitations, and demonstrated regulatory unpredictability.

What Experts Say

Healthcare providers, policy analysts, industry executives, and patient advocates offer diverging perspectives on Texas medical cannabis, with broad consensus that the program underserves patient needs despite disagreement on optimal reform approaches.

The current THC limit forces physicians to recommend products that may be therapeutically inadequate for patients with severe conditions, creating an impossible choice between following the law and providing optimal care.

Medical professionals who participate in TCUP frequently express frustration with the 1% THC limitation, noting that clinical evidence supports higher potencies for conditions like cancer pain, severe PTSD, and treatment-resistant epilepsy. Physicians report that some patients experience inadequate symptom relief from low-THC products, leading them to either suffer unnecessarily or seek higher-potency products through illegal channels. The limited qualifying conditions list also constrains physician discretion, preventing recommendations for patients with conditions like Crohn's disease, Parkinson's disease, or chronic migraines that qualify in other states. Healthcare providers emphasize the need for more robust clinical research, standardized dosing protocols, and integration with electronic health records to normalize cannabis as a legitimate medical intervention. Many physicians remain reluctant to participate in TCUP due to federal illegality concerns, liability uncertainties, and limited clinical training in cannabis medicine, suggesting that program expansion alone won't ensure adequate provider participation without addressing these systemic barriers. Policy analysts view Texas as a case study in incremental reform, where conservative political culture necessitates gradual expansion rather than comprehensive change. Some experts argue this approach builds sustainable support by demonstrating safety and efficacy at each stage, reducing opposition and preventing backlash. Others contend that incremental reforms prolong patient suffering and maintain inefficient market structures that benefit incumbent operators at patient expense. Researchers studying state cannabis policies note that Texas's vertical integration model and limited licensing create market concentration that may reduce innovation and increase prices compared to more competitive structures. However, some analysts argue that tight regulatory control has prevented the compliance failures and public health concerns that have emerged in states with looser oversight, potentially building long-term program legitimacy. Industry executives from existing Texas dispensing organizations defend the current structure as ensuring product quality, preventing diversion, and maintaining political viability. These operators argue that rapid expansion or dramatic policy changes could trigger prohibitionist backlash, jeopardizing the entire program. They emphasize investments in compliance, testing, and patient education that would be difficult to maintain in more competitive markets. Multi-state operators and prospective entrants counter that Texas's limited licensing protects incumbents from competition while failing to serve patient needs. These companies argue that their experience operating in multiple regulatory environments, access to capital, and operational sophistication could improve Texas patient access and product quality. The May 2026 license revocations have intensified these tensions, with excluded operators arguing that political influence rather than merit determined outcomes. Patient advocates consistently emphasize that program restrictions force impossible choices between legal compliance and symptom relief. Veterans organizations particularly stress that PTSD patients often require higher-potency products than Texas allows, forcing veterans to choose between following state law and managing trauma symptoms effectively. Cancer patient advocates note that low-THC products may be insufficient for chemotherapy-induced nausea or severe cancer pain, leaving patients with inadequate treatment options. Advocacy groups argue that Texas's program serves political and business interests rather than patient needs, pointing to the disconnect between the 75,000 current patients and the estimated 1-2 million who could benefit from access. They emphasize that neighboring Oklahoma's success demonstrates that conservative states can implement comprehensive medical programs without the public safety concerns opponents predict. Law enforcement perspectives have evolved as medical cannabis has become normalized nationally. While some sheriffs and police chiefs maintain opposition based on impaired driving and workplace safety concerns, others acknowledge that medical cannabis represents a lower enforcement priority than opioids, methamphetamine, and violent crime. Progressive law enforcement voices argue that regulated medical access reduces illegal market activity and associated violence, creating net public safety benefits. Economic development experts view Texas's restrictive program as a missed opportunity for job creation, tax revenue, and agricultural diversification. Analysts note that cannabis industry development could provide economic lifelines for rural communities facing agricultural challenges, while urban areas could benefit from retail, processing, and ancillary business development. The foregone economic activity from restrictive policies is estimated at hundreds of millions to over a billion dollars annually depending on reform scenarios.

What's Next

Texas medical cannabis faces critical decision points in the 2027 legislative session, ongoing litigation over license revocations, and potential federal policy changes that could reshape the program's legal and economic landscape. The 89th Texas Legislature convenes in January 2027, presenting the next opportunity for statutory changes to TCUP. Multiple bills are expected addressing THC limits, qualifying conditions, licensing expansion, and smokable flower authorization. Representative Stephanie Klick, the program's primary legislative champion, has indicated plans to introduce legislation increasing the THC cap to 5% and adding conditions including Parkinson's disease and Crohn's disease. However, the Republican-controlled legislature's conservative orientation and Governor Abbott's cautious approach to cannabis reform suggest that dramatic changes remain unlikely. Patient advocacy organizations are organizing lobby days and testimony campaigns for the 2027 session, focusing on veterans' PTSD treatment needs and cancer patients' symptom management. These groups plan to present clinical research, patient testimonials, and economic analyses demonstrating program inadequacies and expansion benefits. The effectiveness of these efforts will depend partly on national political trends and whether cannabis reform gains momentum in conservative states. Legal challenges to the May 2026 license revocations will proceed through state courts in late 2026 and 2027. Cresco Labs and other affected operators have retained prominent Texas administrative law attorneys to challenge

Update — May 11, 2026: Texas Revokes Three Conditional Medical Cannabis Permits Including Cresco Labs

The Texas Department of Public Safety abruptly rescinded three conditional licenses that had been awarded to expand the state's Compassionate Use Program, including a permit granted to **Chicago-based multi-state operator Cresco Labs**. The revocations represent a significant setback for the state's limited medical cannabis expansion efforts and mark an unusual reversal in a licensing process that had appeared to be moving forward. **No official explanation for the permit revocations has been publicly released** by state regulators, leaving the affected companies and industry observers without clarity on whether the decision stems from compliance issues, political pressure, or administrative reconsideration.

Cresco Labs, one of the largest cannabis operators in the United States with licenses across multiple medical and adult-use markets, had been positioning to enter Texas as part of its strategic expansion into limited medical programs. **The conditional permits were part of Texas's effort to add licensed dispensing organizations** beyond the original three vertically integrated operators that have served the state's low-THC program since 2017. The revocations effectively freeze the expansion timeline and leave existing license holders—Compassionate Cultivation, Goodblend Texas, and Surterra Wellness—as the sole authorized cultivators and dispensers in the state.

The legal implications of the revocations remain unclear, particularly whether the affected companies will pursue administrative appeals or litigation challenging the state's authority to rescind conditional permits after award. **Conditional licenses typically include contingencies related to background checks, facility inspections, and financial disclosures**, any of which could theoretically trigger revocation if applicants fail to meet requirements. However, the lack of transparency surrounding the DPS decision raises questions about due process and whether applicants were given adequate opportunity to remedy any deficiencies before permits were pulled.

For Texas patients, the revocations mean continued limited access to medical cannabis through the existing three-operator system, which has faced criticism for high prices, limited product selection, and geographic accessibility challenges. The state's Compassionate Use Program remains one of the most restrictive medical cannabis frameworks in the country, with a **maximum THC concentration of 1% by weight** and a qualifying condition list that, while expanded in recent legislative sessions, still excludes many conditions covered in other medical states. The permit revocations signal that Texas regulators may be retreating from incremental expansion rather than accelerating patient access improvements.

Industry analysts note that the revocations could deter future applicants from investing resources in Texas licensing processes if conditional permits can be withdrawn without clear procedural safeguards. The incident also highlights the precarious nature of cannabis licensing in conservative states where medical programs exist within narrow statutory frameworks and face ongoing political scrutiny. Whether the DPS will reissue the permits, open new application windows, or maintain the status quo remains to be seen, but the immediate effect is a contraction rather than expansion of the state's medical cannabis infrastructure.

Update — May 23, 2026: Patient enrollment nears 150,000 as implementation delays persist

Texas's Compassionate Use Program enrolled approximately 150,000 qualified patients as of May 2026, according to state health officials. The milestone follows legislative expansions that added conditions including post-traumatic stress disorder and cancer to the program's qualifying list. Despite the enrollment growth, dispensing organizations reported ongoing delays in product availability tied to cultivation capacity constraints and regulatory bottlenecks at the Department of State Health Services.

Three of the state's licensed dispensaries said supply shortages forced temporary suspensions of new patient intake during April 2026. The Texas Department of State Health Services attributed the delays to extended review timelines for product testing protocols mandated under administrative rules finalized in late 2025. Operators face a minimum 45-day approval window for each new product formulation, limiting the pace at which dispensaries can expand inventory to meet patient demand.

State Representative Stephanie Klick, chair of the House Public Health Committee, said lawmakers are considering amendments to streamline the product approval process during the 2027 legislative session. Industry advocates emphasized that current THC limits of 1 percent by weight remain unchanged despite the enrollment expansion, restricting treatment options for patients with severe symptoms. The cap has drawn criticism from physicians who testified that higher concentrations improve efficacy for conditions like epilepsy and chronic pain.

The enrollment surge matters operationally because dispensing organizations must balance cultivation expansion against regulatory uncertainty. Financial analysts noted that patient growth without corresponding supply infrastructure creates revenue volatility for the state's licensed operators, complicating capital planning and investor confidence in a market still constrained by restrictive THC thresholds and limited qualifying conditions compared to other medical cannabis states.